-
Sector Analysis
Sickle Cell Disease Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2020 – 2030
The US Sickle Cell Disease (SCD) market size was valued at $227.7 million in 2020 and is expected to achieve a CAGR of more than 33% during 2020-2030. Sickle cell disease (SCD) is a genetic, lifelong blood disorder that results in the formation of sickled red blood cells causing severe complications across multiple organ systems. It is inherited in an autosomal recessive pattern, where a single-nucleotide polymorphism in the β-globin gene causes glutamic acid to be replaced by valine, a...
-
Track & Monitor
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q1 2018
GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q1 2018” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q1 2018. The report portrays detailed comparative data on the number of deals and their value in the last...
-
Track & Monitor
Partnerships, Licensing, Investments and M&A Deals and Trends for January 2018 in Pharmaceuticals
The pharmaceutical and healthcare industry reported an increase in the number of deals and deal values in January 2018. The industry reported 413 deals worth USD50.9 billion in January 2018, compared to 410 deals worth USD26.7 billion in December 2017. The oncology therapeutics market remained at the top in deal activity in January 2018 with 148 deals. In second place, central nervous system therapeutics market reported 99 deals. Licensing agreements in pharmaceutical and healthcare industry registered a decrease in upfront...
-
Product Insights
Hemophilia A Global Clinical Trials Review, H2, 2017
GlobalData's clinical trial report, “Hemophilia A Global Clinical Trials Review, H2, 2017" provides an overview of Hemophilia A clinical trials scenario. This report provides top line data relating to the clinical trials on Hemophilia A. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Hemophilia B Global Clinical Trials Review, H2, 2017
GlobalData's clinical trial report, “Hemophilia B Global Clinical Trials Review, H2, 2017" provides an overview of Hemophilia B clinical trials scenario. This report provides top line data relating to the clinical trials on Hemophilia B. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
PharmaPoint: Hemophilia A and B – Global Drug Forecast and Market Analysis to 2026
Hemophilia A and B are rare recessive X-linked genetic deficiencies in the blood clotting factors VIII and IX, respectively, and are characterized by the failure of blood to form normal clots after damage to veins and tissue. In the 7MM, patients with severe forms of the disease are increasingly treated on a prophylactic basis rather than on demand after bleeds. The frequent prophylactic infusions of rFVIII or rFIX begin from the first one or two years of life, often continuing...
-
Track & Monitor
Pharmaceuticals Industry Deals and Trends in Q2 2018 – Partnerships, Licensing, Investments, Mergers and Acquisitions (M&A)
GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q2 2018” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q2 2018. The report portrays detailed comparative data on the number of deals and their value in the last...
-
Sector Analysis
Hemophilia A and B – Global Drug Forecast and Market Analysis to 2028
Hemophilia A and B are rare, genetic, X-linked deficiencies in the blood clotting factors VIII (FVIII) and IX (FIX), respectively. Patients can be categorized as mild, moderate or severe depending on the percentage of circulating FVIII or FIX in their blood. Patients can be treated either on-demand or prophylactically using plasma-derived or recombinant replacement factors, the current standard of care. Although these therapies are effective, they are associated with a great treatment burden. There is a significant unmet need for...